http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Eisenacher, K .,Adesina, Adesoji A . 한국화학공학회 2000 Korean Journal of Chemical Engineering Vol.17 No.1
This paper describes a statistical approach to the optimal selection of preparation conditions for a ceria-promoted Co-Mo catalyst used during CO hydrogenation. Eight catalyst samples based on a full factorial design were prepared via incipient wetness method. Evaluation was carried out in laboratory packed bed reactor using synthesis gas containing H₂:CO=2 at 280℃ and 110 kPa. BET was unaffected by pH although increased calcination temperature induced only a small drop in total surface area. More significantly, catalysts calcined at low temperature (350℃) suffered a 3-fold loss in metal surface area when treated at high temperatures (550℃) while an increase in pH improved the metal area value. pH values above the isoelectric point (IEP=5.65) and low calcination temperature favoured activity and alkene selectivity. High reduction temperature, however, appeared to enhance methane suppression. Additionally, 2-factor interactions were statistically more significant than 3-factor interactions at 95% confidence level. Optimisation of the polynomial models describing the response data was also consistent with qualitative inferences.
Human Brain Proteome Project – 12th HUPO BPP Workshop 26 September 2009, Toronto, Canada
Grö,ttrup, Bernd,Eisenacher, Martin,Stephan, Christian,Marcus, Katrin,Lee, Bonghee,Meyer, Helmut E.,Mok Park, Young WILEY-VCH Verlag 2010 Proteomics Vol.10 No.11
<P>The HUPO Brain Proteome Project (HUPO BPP) held its 12th workshop in Toronto on 26 September 2009 prior to the HUPO VIII World Congress. The principal aim of this project is to obtain a better understanding of neurodiseases and ageing, with the ultimate objective of discovering prognostic and diagnostic biomarkers, in addition to the development of novel diagnostic techniques and new medications. The attendees came together to discuss progress in the human clinical neuroproteomics and to define the needs and guidelines required for more advanced proteomic approaches.</P>
Hamacher, Michael,Stephan, Christian,Eisenacher, Martin,Lewczuk, Piotr,Wiltfang, Jens,Martens, Lennart,Vizcaí,no, Juan Antonio,Kwon, Kyung-Hoon,Yoo, Jong Shin,Park, Young Mok,Beckers, Johannes,H WILEY-VCH Verlag 2007 Proteomics Vol.7 No.15
<P>The Wellcome Trust Conference Centre at Hinxton, UK, was the meeting place of the 7<SUP>th</SUP> HUPO Brain Proteome Project Workshop entitled “High Performance Proteomics”. It started on Wednesday, March 7, 2007 with a steering committee meeting followed by a two days series of talks dealing with the standardization and handling of tissues, body fluids as well as of proteomics data. The presentation and accompanying vivid discussions created a picture of actual strategies and standards in recent proteomics.</P>
Hamacher, Michael,Grö,ttrup, Bernd,Eisenacher, Martin,Marcus, Katrin,Park, Young Mok,Meyer, Helmut E,Kwon, Kyung-Hoon,Stephan, Christian Humana Press 2011 Methods in molecular biology Vol.696 No.-
<P>Several projects were initiated by the Human Proteome Organisation (HUPO) focusing on the proteome analysis of distinct human organs. The initiative dedicated to the brain, its development and correlated diseases is the HUPO Brain Proteome Project (HUPO BPP). An objective data submission, storage, and reprocessing strategy have been established with the help of the results gained in a pilot study phase and within subsequent studies. The bioinformatic relevance of the data is drawn from the inter-laboratory comparisons as well as from the recalculation of all data sets submitted by the different groups. In the following, results of the single groups as well as the centralised reprocessing effort are summarised, demonstrating the added-value of this concerted work.</P>
Hamacher, Michael,Stephan, Christian,Hardt, Tanja,Eisenacher, Martin,Henkel, Andreas,Wiltfang, Jens,Jimenez, Connie R.,Park, Young Mok,Marcus, Katrin,Meyer, Helmut E. WILEY-VCH Verlag 2008 Proteomics Vol.8 No.9
<P>What are the current approaches in brain proteomics? Can we combine different, but complementary study designs to obtain better results concerning brain diseases? What are the neuro-hotspots, especially in Korea? These were some of the questions the participants of the 8<SUP>th</SUP> HUPO Brain Proteome Project Workshop tried to answer prior to the 6<SUP>th</SUP> HUPO World Congress in Seoul, Korea. Around 100 scientists came together during the afternoon of 7 October, 2007, to discuss and to catch up on the latest results and strategies concerning Huntington's disease, glioblastoma and standardization.</P>
Christian Mölleken,Maike Ahrens,Anders Schlosser,Julia Dietz,Martin Eisenacher,Helmut E. Meyer,Wolff Schmiegel,Uffe Holmskov,Christoph Sarrazin,Grith Lykke Sorensen,Barbara Sitek,Thilo Bracht 대한간학회 2019 Clinical and Molecular Hepatology(대한간학회지) Vol.25 No.1
Background/Aims: An estimated 80 million people worldwide are infected with viremic hepatitis C virus (HCV). Even after eradication of HCV with direct acting antivirals (DAAs), hepatic fibrosis remains a risk factor for hepatocarcinogenesis. Recently, we confirmed the applicability of microfibrillar-associated protein 4 (MFAP4) as a serum biomarker for the assessment of hepatic fibrosis. The aim of the present study was to assess the usefulness of MFAP4 as a biomarker of liver fibrosis after HCV eliminating therapy with DAAs. Methods: MFAP4 was measured using an immunoassay in 50 hepatitis C patients at baseline (BL), the end-of-therapy (EoT), and the 12-week follow-up (FU) visit. Changes in MFAP4 from BL to FU and their association with laboratory parameters including alanine aminotransferase (ALT), aspartate aminotransferase (AST), platelets, the AST to platelet ratio index (APRI), fibrosis-4 score (FIB-4), and albumin were analyzed. Results: MFAP4 serum levels were representative of the severity of hepatic fibrosis at BL and correlated well with laboratory parameters, especially APRI (Spearman correlation, R²=0.80). Laboratory parameters decreased significantly from BL to EoT. MFAP4 serum levels were found to decrease from BL and EoT to FU with high statistical significance (Wilcoxon P<0.001 for both). Conclusions: Our findings indicate that viral eradication resulted in reduced MFAP4 serum levels, presumably representing a decrease in hepatic fibrogenesis or fibrosis. Hence, MFAP4 may be a useful tool for risk assessment in hepatitis C patients with advanced fibrosis after eradication of the virus.
Kim, Young Hye,Marcus, Katrin,Grinberg, Lea Tenenholz,Goehler, Heike,Wiltfang, Jens,Stephan, Christian,Eisenacher, Martin,Hardt, Tanja,Martens, Lennart,J Dunn, Michael,Park, Young Mok,Meyer, Helmut E JOHN WILEY & SONS, LTD 2009 PROTEOMICS CLINICAL APPLICATIONS Vol.3 No.9
<P>The HUPO Brain Proteome Project (HUPO BPP) held its 11th workshop in Kolymbari on March 3, 2009. The principal aim of this project is to obtain a better understanding of neurodiseases and ageing, with the ultimate objective of discovering prognostic and diagnostic biomarkers, in addition to the development of novel diagnostic techniques and new medications. The attendees came together to discuss sub-project progress in the clinical neuroproteomics of human or mouse models of Alzheimer's and Parkinson's disease, and to define the needs and guidelines required for more advanced proteomics approaches. With the election of new steering committees, the members of the HUPO BPP elaborated an actual plan promoting activities, outcomes, and future directions of the HUPO BPP to acquire new funding and new participants.</P>